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Abstract
mRNA modification by N6-methyladenosine (m6A) is involved in many post-transcriptional
regulation processes including mRNA stability, splicing and promotion of translation.
Accordingly, the recently identified mRNA methylation complex containing METTL3,
METTL14, and WTAP has been the subject of intense study. However, METTL16
(METT10D) has also been identified as an RNA m6A methyltransferase that can methylate
both coding and noncoding RNAs, but its biological role remains unclear. While global stud-
ies have identified many potential RNA targets of METTL16, only a handful, including the
long noncoding RNA MALAT1, the snRNA U6, as well as the mRNA MAT2A have been veri-
fied and/or studied to any great extent. In this study we identified/verified METTL16 targets
by immunoprecipitation of both endogenous as well as exogenous FLAG-tagged protein.
Interestingly, exogenously overexpressed METTL16 differed from the endogenous protein
in its relative affinity for RNA targets which prompted us to investigate METTL16’s localiza-
tion within the cell. Surprisingly, biochemical fractionation revealed that a majority of
METTL16 protein resides in the cytoplasm of a number of cells. Furthermore, siRNA knock-
down of METTL16 resulted in expression changes of a few mRNA targets suggesting that
METTL16 may play a role in regulating gene expression. Thus, while METTL16 has been
reported to be a nuclear protein, our findings suggest that METTL16 is also a cytoplasmic
methyltransferase that may alter its RNA binding preferences depending on its cellular local-
ization. Future studies will seek to confirm differences between cytoplasmic and nuclear
RNA targets in addition to exploring the physiological role of METTL16 through long-term
knockdown.
Introduction
Methylation on the sixth position of the base moiety of adenosine (m6A) is one of the most
common mRNA modifications in eukaryotes, and it has been shown to affect all aspects of
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post-transcriptional regulation including mRNA splicing, stability, and translation [1–9].
Methyltransferase like -3 and -14 (METTL3 and METTL14) and Wilms’ tumor associating
protein (WTAP) in addition to KIAA1429 are all components of the mRNA m6A methyltrans-
ferase complex, which uses a S-adenosyl methionine (SAM) binding domain on METTL3 to
methylate specific mRNAs for methylation with a RRACH m6A consensus sequence [10–15].
Many RNA binding proteins (RBPs) including the YTH family of proteins modulate the effects
of m6A through specific binding to the methylated RNA. For example, YTHDF1 has been
shown to increase translation of m6A containing mRNA, while YTHDF2 appears to direct
mRNA degradation and YTHDF3 appears to play roles in both processes [5–8, 16, 17]. m6A
has been shown to play a role in a number of physiological processes including embryonic
stem cell differentiation, circadian rhythms, response to hypoxia and other stressors, and is
implicated in many different aspects of cancer [1, 9, 16, 18–27].
METTL16 has also been identified as an RNA m6A methyltransferase that methylates both
coding and noncoding RNAs. Primarily, METTL16 has been shown to methylate the U6
snRNA [28, 29]. It can also bind and methylate the long noncoding RNAs MALAT1 and XIST
[28, 30]. In addition, METTL16 has been shown to bind and methylate mRNAs, including
MAT2A, which can regulate its alternative splicing in response to cellular SAM levels [29, 31,
32]. Furthermore, global analysis suggests that many other mRNAs including RBM3 and
STUB1 may also be METTL16 targets [28].
Perhaps the most intriguing aspect of the METTL16 methyltransferase is the importance of
structure when binding targets, not just sequence like the METTL3/METTL14/WTAP com-
plex. METTL16 m6A methylation of MAT2A is reliant upon a conserved hairpin (hp1) for
binding and a similar sequence and structure is required for U6 methylation as well, but inter-
estingly, is not readily apparent in other METTL16 targets [29]. In in vitro methylation studies,
METTL16 appears to prefer stem loop structures with the methylated adenosine being
unpaired in a single stranded loop or bulge [31, 33]. Additionally, instead of the heterodimeric
“writer” complex formed by METTL3/METTL14/WTAP m6A methyltransferase, METTL16
functions as a homodimer [34]. This homodimeric METTL16 is necessary for binding the
MALAT1 triple helix, although monomeric METTL16_291, which contains only the methyl-
transferase domain, is sufficient for methylating U6 and MAT2A RNAs [29, 34].
At a molecular level, the effects of METTL16 m6A activity are best understood in the con-
text of cellular S-adenosylmethionine (SAM) levels and intron retention of MAT2A pre-
mRNA. SAM is a methyl donor for most cellular methylation reactions and is created using
SAM synthetases that convert methionine and ATP into SAM [29]. In human cells, the SAM
synthetase is encoded by the MAT2A gene and is expressed in all cell types except liver cells.
Methionine depletion stabilizes MAT2A mRNA, which has six hairpin structures (hp1-6) in
its 3’ UTR that serve as binding sites for METTL16. When intracellular SAM levels are high,
METTL16 binds the hp1 of MAT2A RNA, methylates it, and quickly dissociates to support
intron retention. Intron retention targets the MAT2A mRNA for nuclear degradation. Low
intracellular levels of SAM do not allow for efficient methylation by METTL16, increasing
METTL16 occupancy on the mRNA which results in increased splicing of the retained intron.
This increases stabilization and translation of the MAT2A mRNA and production of SAM
synthetase which increases SAM levels in the cell. Additionally, the YTHDC1 m6A “reader”
protein may play a role in processing the mature MAT2A mRNA and monitoring intracellular
SAM levels [32].
Other than regulating MAT2A in response to SAM levels, the physiological significance of
METTL16 is largely unknown at this point. METTL16 does appear to be vital for the prolifera-
tion/survival of a number of cancer cells [35] and has been identified in a number of screens
for essential genes [36–40]. Interestingly, whole mouse METTL16 knockout results in
METTL16 is cytoplasmic
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blastocysts that are unfit to develop further and abort, although the reason for this is not defin-
itively known, but may also be due to regulation of MAT2A expression [31]. Thus, METTL16
appears to be essential for mammalian life, even though its physiological role has not been
fully characterized.
In this study, we have confirmed that METTL16 binds a number of coding and noncoding
RNAs and identify a number of novel METTL16 targets. In addition, we show that overexpres-
sion of METTL16 can affect both its cellular location as well as its RNA binding preferences.
Our results suggest that the majority of METTL16 protein resides in the cytoplasm of a num-
ber of cell types, and that knockdown of METTL16 protein can affect the expression of a few
of its mRNA binding targets. These results suggest that METTL16 may have additional roles in
the cell that could contribute to its essentiality.
Results
Identification of METTL16 binding targets
To identify potential METTL16 RNA targets as well as verify reported literature targets,
HEK293T cells were transiently transfected with either FLAG-GFP or FLAG-METTL16 over-
expression constructs. Cell extracts were then subjected to Ribonucleoprotein Immunoprecip-
itation (IP) using FLAG magnetic beads. Western blotting was used to confirm successful
immunoprecipitation as evidenced by depletion of the expected band in the supernatant and
enrichment in the IP (Fig 1A). RNA was also extracted, and real-time PCR was used to mea-
sure enrichment of METTL16 targets. Two methods were used to calculate enrichment. In the
first analysis, the amount of the RNA target in the GFP or METTL16 IP was compared to the
input levels from 50% of the sample to generate a relative enrichment (Fig 1B, left panels). Spe-
cifically, the value is a fold enrichment in the IP relative to the Input and is calculated by rais-
ing two to the power of the Cq value of the IP subtracted from the Cq value of the Input. In the
second analysis, fold enrichment of the RNA target in the METTL16 IP compared to the GFP
IP was calculated (Fig 1B, right panels) by dividing the METTL16 relative enrichment (as
described above) by the GFP relative enrichment value. By comparing enrichment to both the
input as well as a negative IP we can get a better sense of the nature of the binding and have
greater confidence in identifying METTL16 binding targets. As shown in Fig 1B, U6 snRNA
appears to be the primary binding target of METTL16 by either analysis. Importantly, U1 and
U2 snRNA, which are not known to harbor an m6A, served as negative controls and exhibited
very little enrichment in the METTL16 IP. It does appear that 18S rRNA is also a target, show-
ing an almost 1,000-fold enrichment in the METTL16 IP over the GFP IP. Interestingly, in
addition to MAT2A, a number of mRNA’s including β2M, MYC, and NT5DC2 also appeared
to be FLAG-METTL16 targets, while the long noncoding RNA (lncRNA) MALAT1 did not
appear to be bound by FLAG-METTL16.
To determine if these targets were the same for endogenous METTL16, we repeated the
immunoprecipitation in HEK293T extracts using either METTL16 antibody or normal rabbit
serum (NRS) coated magnetic beads. Western blotting confirmed that the IP was successful
with METTL16 protein remaining in the supernatant of the negative IP while appearing in the
IP lane of the METTL16 antibody (Fig 2A). Real-Time PCR was again used to measure RNA
enrichment of targets either compared to the input levels (Fig 2B, left panels) or in relation to
the negative IP after normalizing for input levels (Fig 2B, right panels). Interestingly, in con-
trast to the FLAG-METTL16 immunoprecipitation, MAT2A mRNA appeared to be the pri-
mary target of endogenous METTL16, although U6 snRNA was still a significant target.
Additional mRNAs such as HIF-1α, MYC, and NT5DC2 were also identified as potential
METTL16 targets while 5S rRNA and U1 and U2 snRNA appear to not be bound by
METTL16 is cytoplasmic
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Fig 1. Identification of FLAG-METTL16 targets. FLAG-METTL16 or FLAG-GFP protein was overexpressed and
immunoprecipitated from HEK293T cells. (A) Input, Supernatant (Sup), and Immunoprecipitated (IP) protein were
subjected to Western blotting to confirm successful immunoprecipitation (Antibody Heavy Chain (H.C.) and Light
Chain (L.C) are indicated). (B) Associated RNAs were isolated via Trizol and real-time PCR was used to determine
enrichment. The left panel depicts data as relative enrichment compared to the input, while the right panel shows
METTL16 is cytoplasmic
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METTL16, which is expected given that they are not known to be m6A methylated. In contrast
to the FLAG-IP, the lncRNA MALAT1 did appear to be a binding target of the endogenous
METTL16.
Investigation of METTL16 cellular localization
Based on the differences in targets between exogenous FLAG-tagged and endogenous
METTL16, we theorized that METTL16 localization may change based on expression levels
and that this may impact target selection. Biochemical fractionation of FLAG-METTL16 over-
expressing HEK293T cells revealed that exogenously expressed METTL16 protein was found
in both the cytoplasmic and nuclear fractions (55% in cytoplasm; 45% in nucleus) (Fig 3A).
Lactate Dehydrogenase (LDH) served as a marker for the cytoplasmic fractions, while the
nuclear matrix protein Lamin B and the transcription factor Specificity Protein 1 (SP1) served
as markers for the insoluble and soluble nuclear fractions respectively and confirm successful
fractionation. To investigate whether overexpression affected METTL16 cellular localization
we also analyzed endogenous METTL16’s localization in HEK293T cells using biochemical
fractionation (Fig 3B). Compared to the FLAG-overexpressed METTL16, slightly more endog-
enous METTL16 was found in the cytoplasm (60%) relative to the nucleus (40%). These results
suggest that overexpression of METTL16 may affect its cellular localization and that this may
impact the RNA targets identified in the immunoprecipitations.
Previously, METTL16 has been reported to be a predominantly nuclear protein [28–30,
41]. Using an antibody from a previous study we attempted to use immunohistochemistry to
verify METTL16’s cellular localization [30]. Initial experiments showed METTL16 staining in
both the cytoplasm and nucleus of HEK293T cells (S1 Fig). To validate antibody specificity, we
ran both Western blotting and immunohistochemistry on control and METTL16 siRNA
knockdown HEK293T cells. Despite almost complete knockdown of METTL16 protein by
siRNA (as confirmed by western blotting) similar staining patterns and intensities were
observed in both control and METTL16 siRNA treated samples suggesting that the immuno-
histochemical staining observed may be non-specific (S1 Fig). A second antibody gave similar
results with fluorescent signal in both the cytoplasm and nucleus of HEK293T cells. However,
once again, the signal was not decreased in the immunohistochemistry when METTL16 was
depleted with long-term (6 day) siRNA treatment suggesting that the majority of the signal
from this antibody is also coming from non-specific binding (S2 Fig).
As an alternative approach, we again used biochemical fractionation to examine
METTL16’s localization in two other cell lines in which immunohistochemistry had indicated
nuclear localization [28, 30]. As shown in Fig 4A, in HEK293 cells, METTL16 protein appears
to be predominately located in the cytoplasm with almost 90% of the protein in the cytoplasm,
while in the HELA cells approximately 55% of METTL16 protein appears cytoplasmic. To
determine if this a more widespread observation, we also examined METTL16’s localization in
a lung fibroblast cell line (CCD34LU) as well as a lung cancer cell line (NCI-H1299) and again
found METTL16 to be predominant in the cytoplasm of both cell types (Fig 4B). We also
examined METTL16’s localization in a series of MCF10 breast cancer cells representing
different stages of breast cancer progression. MCF10-A’s represent immortalized, yet non-
tumorigenic cells. MCF10-AT1’s are transformed but are weakly tumorigenic, while the
MCF10-Ca1h line represents a highly aggressive tumorigenic cell line [42, 43]. Again, we saw
at least 50% of METTL16 protein located in the cytoplasm of all three of these cell lines (Fig
enrichment in the METTL16 relative to the FLAG-GFP control immunoprecipitation. (�) P� 0.05, (#) P�0.1 by paired
Student’s t-test. Error bars represent SEM of four to seven experiments.
https://doi.org/10.1371/journal.pone.0227647.g001
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Fig 2. Identification of endogenous METTL16 targets. HEK293T extracts were immunoprecipitated with either
METTL16 antibody or normal rabbit serum (NRS) as a negative control. (A) Input, Supernatant (Sup), and
Immunoprecipitated (IP) protein were subjected to Western blotting to confirm successful immunoprecipitation
(Antibody Heavy Chain (H.C.) is indicated). (B) Associated RNAs were isolated via Trizol and real-time PCR was used
to determine enrichment. The left panel depicts data as relative enrichment compared to the input, while the right
panel shows enrichment in the METTL16 relative to the FLAG-GFP control immunoprecipitation. (�) P� 0.05, (#)
P�0.1 by paired Student’s t-test. Error bars represent SEM of six experiments.
https://doi.org/10.1371/journal.pone.0227647.g002
METTL16 is cytoplasmic
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4C), confirming that in addition to its reported nuclear localization, METTL16 protein is
found in the cytoplasm of a number of cell types and localization does not appear to be affected
by transformation.
Effect of METTL16 knockdown on target expression
We attempted to determine the physiological role of METTL16 by knocking it out using
CRISPR, but we were unable to create stable cell lines. This is in line with previous literature
reports that suggest that METTL16 is likely an essential gene [29, 36]. METTL16 was instead
Fig 3. Determination of METTL16 cellular localization in HEK293T cells. (A) Extracts from HEK293T cells stably expressing
FLAG-METTL16 or an empty vector control were separated into Total, Insoluble Nuclear (Nuc-IS), Cytoplasmic (Cyto), and Soluble
Nuclear (Nuc-S) fractions and subjected to Western blot with METTL16 antibody to determine METTL16 cellular localization. Lamin B
was used as an insoluble nuclear marker, SP1 as a soluble nuclear marker, and lactate dehydrogenase (LDH) as a cytoplasmic marker. (B)
Biochemical cellular fractionation was also used to determine the location of endogenous METTL16 protein in untreated HEK293T
cells. (representative of three to five experiments).
https://doi.org/10.1371/journal.pone.0227647.g003
METTL16 is cytoplasmic
PLOS ONE | https://doi.org/10.1371/journal.pone.0227647 January 15, 2020 7 / 18
METTL16 is cytoplasmic
PLOS ONE | https://doi.org/10.1371/journal.pone.0227647 January 15, 2020 8 / 18
knocked down for an extended period of time using siRNA. In this set of experiments,
HEK293T cells were transfected with either a scrambled negative control siRNA or one of two
METTL16-specific siRNAs. After 48 hours of siRNA expression, cells were harvested or
replated and retransfected the following day with the same siRNA. Cells were then harvested 6
days after the initial transfection (3 days after the 2nd transfection). Western blotting con-
firmed that compared to the negative control siRNA, treatment with either METTL16 siRNA
resulted in significant knockdown of METTL16 expression at both the RNA (Fig 5A) and pro-
tein (Fig 6) level, with 6 days treatment resulting in almost complete loss of the protein. Real-
time PCR was then used to assess the effect of METTL16 knockdown on the expression of
METTL16 target RNAs. As shown in Fig 5A, 48 hour knockdown of METTL16 caused small
changes in expression of a number of RNAs but significantly increased the expression of
NT5DC2 mRNA. Interestingly, many of these changes were reduced, lost, or even reversed
after 6 days of METTL16 knockdown, and instead we observed decreases in the MALAT1
lncRNA and STUB1 mRNAs (Fig 5B) although it was only with the #7 siRNA that showed
greater METTL16 knockdown. No changes were seen in the expression levels of a number of
other coding and noncoding RNAs. Consistent with the real-time PCR results, we saw little to
no effect of METTL16 knockdown on the protein expression of any of the targets tested (Fig
6).
Discussion
Overall, our work provides new insight into both the targets of METTL16 as well as its poten-
tial for the regulation of gene expression while also raising some new questions about
METTL16’s role in the cell. Through immunoprecipitation we have verified the three most
well-defined and researched METTL16 RNA substrates [28–30]. While U6 snRNA was the
preferred target of FLAG-METTL16, it appears that MAT2A may be the preferred endogenous
target in HEK293Ts. We also verified the first identified METTL16 target, lncRNA MALAT1
[30]. Previous reports have found METTL16 bound to ribosomal RNA [28], and our data sug-
gests that 18S rRNA is the preferred target. However, recent studies have identified ZCCHC4
and METTL5 as the 28S and 18S rRNA m6A methyltransferases respectively [44, 45]. This
raises the question as to whether the rRNAs are indeed specific binding targets of METTL16,
and if they are, what role might METTL16 be playing.
While MAT2A was clearly the preferred mRNA binding target of METTL16 in our system,
we were also able to confirm a number of other mRNA binding targets including RBM3,
STUB1, and NT5DC2 identified in previous studies [28, 29]. In addition, our studies have
identified several novel mRNAs including β2M, HIF-1α and MYC which also appear to be
bound by METTL16. However, our long-term knockdown studies failed to reveal any signifi-
cant expression changes at either the RNA or protein level of these targets. The question of
whether these mRNAs are regulated in some way by METTL16 methylation or even
METTL16 protein binding remains to be determined.
The change in target preference that we saw between exogenous and endogenous
METTL16 immunoprecipitations made us question whether expression levels might impact
METTL16 cellular localization, and in turn, modulate its binding preferences. Biochemical
fractionation of HEK293T cells suggests that a majority of METTL16 protein is localized to the
Fig 4. Determination of METTL16 cellular localization in multiple cell lines. (A) Extracts from HEK293 or HELA cells were separated into Total,
Cytoplasmic (Cyto), Soluble Nuclear (Nuc-S), and Insoluble Nuclear (Nuc-IS) fractions and subjected to Western blot with METTL16 antibody to
determine METTL16 cellular localization. Lamin B was used as an insoluble nuclear marker, SP1 as a soluble nuclear marker, and lactate dehydrogenase
(LDH) as a cytoplasmic marker. (B, C) Biochemical cellular fractionation was also used to determine the location of METTL16 protein in lung cell lines
CCD34LU and NCI-H1299 as well as breast cancer cell lines MCF10-Ca1h, MCF10-AT1, and MCF10-A. (representative of two to three experiments).
https://doi.org/10.1371/journal.pone.0227647.g004
METTL16 is cytoplasmic
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cytoplasm with lesser amounts of protein found in the nucleus. This contradicts previous char-
acterizations of METTL16 as a predominately nuclear m6A methyltransferase [28–30, 41]. We
also observed cytoplasmic METTL16 localization in a number of other cell types representing
normal cells as well as different stages of cancer suggesting that this may be a more general
finding relevant to all cell types.
Fig 5. Effect of METTL16 knockdown on mRNA expression. HEK293T cells were treated for 2 days (A, C) or 6 days
(B, D) using either a negative control siRNA (Neg) or one of two METTL16-specific (7 & 9) siRNAs. Real-time PCR
was used to determine the effect on RNA expression normalized to GAPDH and expressed as relative to the negative
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Our attempts to verify the biochemical fractionation results with immunohistochemistry
were unsuccessful due to non-specific binding of the antibodies tested. This was quite surpris-
ing as the antibodies were verified to recognize METTL16 in western blotting as confirmed by
loss of signal with long-term siRNA treatment. However, when siRNA knockdown cells were
probed for METTL16 by immunohistochemistry, similar signal intensities and localization
were seen, suggesting that in immunohistochemistry the antibodies were recognizing other
antigens. This explanation is supported by the fact that non-specific bands were also observed
in the Western blotting and may be contributing to this erroneous signal. Thus, we feel the
immunohistochemistry results are suspect until a specific antibody can be verified.
While it is clear from our fractionation data that METTL16 can be found in the cytoplasm
of cells, all of its currently reported activities take place in the nucleus [29, 32, 41]. Splicing of
MAT2A is clearly a nuclear activity, as is U6 snRNA processing. Small amounts of U6 snRNA
have been found in the cytoplasm but it is not clear if this is a widespread phenomenon [46,
47]. Finally, to date, the majority of METTL16-mediated methylations have been identified in
introns [28], which again suggests a nuclear role for the protein. While we have clearly shown
METTL16 protein in the cytoplasm of cells, the role it plays there is unclear. It is interesting
that in our study, all of our primers were directed to mature mRNA and do not amplify pre-
mRNA, which suggests that METTL16 can bind to mature mRNA, although we did not inves-
tigate its methylation of those mRNA.
METTL16 is essential for mammalian life based on our (and others) attempts at creating
METTL16 knockout cell lines via CRISPR and knockout studies in mice embryos [29, 31].
This observation is also supported by global screens for essential genes that have identified
METTL16 [36–40]. The reason for its essentiality is unclear, but it has been implicated in two
major roles in cellular development and survival. It is clear that METTL16’s regulation of
MAT2A mRNA levels via the SAM synthetase pathway affects developmental events [31].
Fig 6. Effect of METTL16 knockdown on protein expression. HEK293T cells were treated for 2 days (A) or 6 days
(B) using either a negative control siRNA (Neg) or one of two METTL16-specific (7 & 9) siRNAs. Western blotting
was used to determine the effect on protein expression. (representative of five experiments).
https://doi.org/10.1371/journal.pone.0227647.g006
METTL16 is cytoplasmic
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METTL16 knockout downregulates MAT2A mRNA levels, which likely leads to the produc-
tion of blastocysts that are not capable of further development. It is also possible that
METTL16-mediated m6A methylation of U6 snRNA is important for proper functionality of
the spliceosome complex, and the lack of this modification could have global effects on splicing
that result in production of incorrect proteins and eventual cell death. It is known that the
methylated adenosine (A43) is essential for U6 snRNAs function in yeast [48], however, wide-
spread changes in splicing were not observed in the knockout mouse studies [31], raising the
question of whether the methylation of this residue of U6 snRNA impacts splicing in any
appreciable way.
Given that METTL16 appears to be essential, conditional knockout/knockdown models
will need to be developed to better investigate the effects of METTL16 methylation on mRNA
stability, translation, as well as splicing via U6. Of particular interest will be determining
whether there are differences between METTL16-mediated methylation and METTL3-me-
diated methylation, particularly in the RNA binding proteins which recognize the methylation
and/or the functional consequences of methylation. In the future, it will be interesting to create
METTL16 variants with localization sequences that force the protein to either the nucleus or
cytoplasm. These variants can be used to determine the binding preferences of METTL16
based on its localization, which may explain the differences we have seen in this study.
Materials and methods
Tissue culture
HEK293T, HEK293, HELA, CCD34LU and NCI-H1299 cells were obtained directly from
ATCC. MCF10-A, MCF10-AT1, and MCF10-Ca1h were obtained from Barbara Ann Karma-
nos Cancer Center. Cells were routinely cultured at 37˚C, 5% CO2. HEK293T, HEK293, and
HELA cells were maintained in DMEM with 4g/L glucose, 10% FBS, 2 mM L-glutamine, and
1X Pen/Strep. CCD34LU cells were maintained in EMEM with 10% FBS, and 1X Pen/Strep.
NCI-H1299 cells were maintained in RPMI-1640 with 4g/L glucose with 10% FBS, 2 mM
L-glutamine, and 1X Pen/Strep. MCF10-A, MCF-AT1, and MCF10-Ca1h cells were main-
tained in a 50/50 mix of DMEM/F12 with 5% horse serum, 1mM CaCl2, and 1X Pen/Strep,
10 μg/ml insulin, 20 ng/ml EGF, 0.5 μg/ml Hydrocortisone, and 0.1 μg/ml cholera enterotoxin.
Knockdown and overexpression of METTL16
For knockdown, HEK293T cells were transfected with 20 μM siRNA (Life Technology Silencer
Select) targeting METTL16 (siRNA ID# S35507 or S35509) or Negative Control #1 (Catalog #
AM4635) siRNA with Lipofectamine 2000 (Thermo Fisher) according to manufacturer’s
directions. For long-term knockdown, cells were transfected and allowed to recover for 48
hours. Cells were lifted, counted and replated for 2nd round of transfection while the remain-
der of the cells were harvested for RNA and protein. The following day cells were transfected
again and allowed to recover for 3 more days before final harvesting (6 days knockdown
total). For overexpression, 2 μg of plasmid expressing a FLAG-tagged METTL16 (Origene:
RC208648) or GFP were used. Cells were transfected for 72 hours before harvesting to allow
for sufficient overexpression of METTL16.
Western blots
Whole-cell lysates were prepared in whole-cell extract buffer (WCEB: 50 mM Tris pH 7.4, 150
mM NaCl, 5 mM EDTA, 0.1%SDS, and complete protease inhibitor [Promega]). After sonica-
tion, equal amounts of protein (30–50 μg) were electrophoresed on a mini-PROTEAN any KD
METTL16 is cytoplasmic
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acrylamide gel (Bio-Rad Laboratories) and transferred to Hybond ECL nitrocellulose (GE
Healthcare). The blot was blocked with 5% non-fat dry milk (LabScientific) in Tris-buffered
saline with 0.1% Tween 20 (TBST) for 1 hour at room temperature, followed by primary anti-
body incubation in blocking buffer overnight at 4˚C. After washing extensively with TBST,
blots were incubated for 1–2 hour at room temperature with appropriate HRP-linked second-
ary antibody (GE Healthcare), washed again with TBST, developed using Bio-Rad Clarity
Western ECL Substrate (Bio-Rad Laboratories), and imaged via MYECL Imager (Thermo Sci-
entific). Antibody details including working dilutions can be found in S1 Table.
RNA extraction
Trizol (Life Technologies) was used for all RNA extractions according to the manufacturer’s
protocol. For RNA extraction from ribonucleoprotein immunoprecipitations (RIP), GlycoBlue
(Life Technologies) was added as a carrier during the precipitation step. RNA quality and
quantity were determined via NanoDrop 1000 (ThermoFisher Scientific).
PCR
Reverse transcription was performed on 1 μg of total RNA in a 20 μl reaction with the iScript
cDNA synthesis kit (Bio-Rad Laboratories,170–8891). Quantitative real-time PCR was per-
formed using a Roche Lightcycler 96 with Fast Start Essential DNA Green (Roche Diagnostics
Corporation, 06-924-204-001) and primers from Integrated DNA Technologies, Inc. Primer
efficiency was verified to be over 95% for all primer sets used. Quantification of mRNA was
carried out via ΔΔCT analysis using GAPDH mRNA and the respective control condition for
normalization. All real-time PCR primer sets were designed so the products would span at
least one intron (>1kb when possible) to prevent detection of the pre-mRNA and/or DNA,
and amplification of a single product was confirmed by agarose gel visualization and/or melt-
ing curve analysis (See S2 Table for sequences).
FLAG immunoprecipitation of METTL16
Beads labeled with FLAG Antibody (Sigma) were washed and resuspended in NT2 buffer (50
mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM MgCl2, 0.05% NP40) supplemented with 1 mM
DTT, 100 units/ml RNase Out and 20mM EDTA. Cells were harvested in Polysome Lysis
Buffer (PLB; (100 mM KCl, 5 mM MgCl2, 10 mM HEPES (pH 7.0), 0.5% NP40, 1 mM DTT,
100 units/ml RNase Out, with Protease inhibitor cocktail)) and equal amounts of lysate were
added to each IP reaction and tumbled for 4 hours at 4˚C. After washing 5 times with NT2,
beads were resuspended in Trizol for RNA or WCEB with protease inhibitors (PI) for protein.
Relative and fold enrichment of RNA in the IP was determined as indicated in the results
section.
Immunoprecipitation of endogenous METTL16
Cells were harvested in PLB. Beads labeled with METTL16 Antibody (Bethyl Laboratories) or
normal rabbit serum (NRS) were washed and resuspended in NT2 supplemented with 1 mM
DTT, 100 units/ml RNase Out and 20mM EDTA. Equal amounts of lysate were added to each
IP and tumbled for 4 hours at 4˚C. After washing, beads were lysed in Trizol (RNA) or WCEB
(protein). Relative and fold enrichment was determined as indicated in the results section.
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Cell fractionation
For total extracts, 10% of the cells were lysed in WCEB with Pierce protease inhibitor cocktail
(PI; Thermo Scientific). The remaining cells were resuspended in hypotonic buffer (10 mM
NaCl, 10 mM Tris-HCl, pH 7.4, 1.5 mM MgCl2 with PI) and incubated on ice for 5 minutes
before freezing at -80˚C. After thawing on ice, lysis was achieved by vortexing for 2–3 seconds
and nuclei were pelleted at 1,000 xG for 5 minutes at 4˚C. The supernatant was removed and
stored as cytoplasmic fraction. The pellet was then resuspended in the above buffer containing
1% NP40 and 0.5% sodium deoxycholate and centrifuging at 1,000 xG for 5 minutes at 4˚C.
The supernatant after centrifugation was designated the soluble nuclear fraction. The remain-
ing insoluble nuclear pellet was sonicated in WCEB with PI. Equal volumes of each fraction
were subjected to western blotting as described above. MyImage Analysis (Thermo Scientific)
was used to quantify the bands in the cytoplasmic, soluble nuclear and insoluble nuclear frac-
tions. Data were expressed as a percentage of the total protein (summed from the three frac-
tions) found in each fraction.
Immunohistochemistry
HEK293T cells with or without 6 days of siRNA treatment (as described above) were fixed in
either ice cold 4% paraformaldehyde or 95% methanol/5% acetic acid for 15mins. Paraformal-
dehyde-treated cells were permeabilized with 0.1% Triton in PBS for 10 minutes. After wash-
ing with PBS, cells were blocked with 1% BSA in PBS at 4˚C for at least 1 hour. Primary
antibody incubation was performed for at least 16 hours in blocking buffer, followed by exten-
sive washing in PBS. Secondary antibody incubation was performed for 1.5 hours in blocking
buffer at room temperature in the dark, followed by extensive washing with PBS. Cells were
then counterstained with DAPI before being imaged on an Olympus IX73 inverted compound
microscope. Images were captured with Olympus cellSens software using default settings.
Briefly, a random field of Neg siRNA treated cells were imaged for phase contrast, FITC, and
DAPI and the exposure times for the FITC and DAPI stains were then used for subsequent
images of the siRNA treated cells to allow for comparison between the two conditions. A sec-
ondary antibody-only control was also imaged with this same exposure. All individual images
were converted to lossless JPEGs without any modifications from the original .vsi file. The
“Combine Channels” option in the cellSens software was used to create the FITC/DAPI over-
lays. For clearer visualization and background reduction, the overlays were subjected to the
“Optimize Contrast” option in the cellSens software.
Statistical analysis
All experiments were performed on at least three separate occasions to generate biological rep-
licates unless otherwise indicated. For the immunoprecipitations, statistical significance was
calculated by a two-tailed, paired Student’s t-test comparing the METTL16 IP to the GFP or
NRS IP. Outliers were identified utilizing the Grubb’s test but only one outlier was ever
removed for a given RNA target. For the real time analysis of the siRNA knockdown experi-
ments, a one-way ANOVA with post-hoc Tukey HSD test was run for each RNA target com-
paring all six conditions. For all experiments, a P-value below 0.05 was defined as statistically
significant, while a P-value less than 0.1 was considered reportable.
Supporting information
S1 File. Raw Western blot images.
(PDF)
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S1 Fig. Validation of HPA020352 METTL16 antibody. (A) Methanol fixed HEK293T cells
subjected to immunohistochemistry with METTL16 antibody and DAPI nuclear stain. (B)
HEK293T cells were treated for 6 days with either a negative control siRNA (Neg) or
METTL16-specific siRNAs. Western blotting indicated substantial METTL16 knockdown
(similar to Fig 6) with additional non-specific background bands. Immunohistochemistry on
methanol fixed cells from the same experiment showed similar staining in both location and
intensity despite METTL16 knockdown suggesting non-specific binding.
(TIF)
S2 Fig. Immunohistochemistry with second METTL16 antibody. HEK293T cells were
treated for 6 days with either a negative control siRNA (Neg) or METTL16-specific siRNAs.
Immunohistochemistry on paraformaldehyde fixed cells with PA5-54185 METTL16 antibody
showed similar staining in both location and intensity despite METTL16 knockdown suggest-
ing non-specific binding. DAPI was used to visualize the nucleus.
(TIF)
S1 Table. Antibodies used in this study.
(DOCX)
S2 Table. Real time PCR primers used in this study.
(DOCX)
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